Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

Posted by Brian Himes on Jun 5th, 2026

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the sale, the director owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. This trade represents a 0.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $105,600.00.
On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total value of $93,000.00.

Recursion Pharmaceuticals Stock Up 9.5%

Shares of Recursion Pharmaceuticals stock opened at $3.80 on Friday. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $3.30 and a two-hundred day moving average price of $3.82. The stock has a market capitalization of $2.01 billion, a P/E ratio of -3.17 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same quarter last year, the firm posted ($0.50) earnings per share. The company’s quarterly revenue was down 56.8% compared to the same quarter last year. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on RXRX. Bank of America cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Morgan Stanley increased their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.10.

Get Our Latest Analysis on RXRX

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RXRX. Bank of America Corp DE boosted its stake in Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Recursion Pharmaceuticals by 59.4% in the 1st quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock valued at $675,000 after buying an additional 82,100 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Recursion Pharmaceuticals by 64.0% during the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock worth $1,764,000 after acquiring an additional 224,332 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Recursion Pharmaceuticals by 7.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock valued at $675,000 after acquiring an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $236,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.